Side effects of cytokines approved for therapy (Q38255698)

1 September 2017

1 reference

title

Side effects of cytokines approved for therapy (English)

1 reference

1 September 2017

Brian A Baldo

1

1 reference

1 September 2017

1 November 2014

1 reference

1 September 2017

1 reference

1 September 2017

37

1 reference

1 September 2017

921-943

1 reference

1 September 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1007/s40264-014-0226-z

1 September 2017

0 references

cites work

Protein therapeutics: a summary and pharmacological classification

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Molecular engineering of antibodies for therapeutic and diagnostic purposes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Optimizing therapeutic antibody function: progress with Fc domain engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Antibody-drug conjugates: targeted drug delivery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

The safety and side effects of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Large-scale transient expression in mammalian cells for recombinant protein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Protein engineering 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Development and characterization of novel erythropoiesis stimulating protein (NESP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

2. Cytokines and chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

3. Cytokines and chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Cytokines and anti-cytokines as therapeutics--an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Trial Watch: Immunostimulatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Adverse effects of drugs in the treatment of viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Clinical allergy. Managing generalized interferon-induced eruptions and the effectiveness of desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Multiple sclerosis: side effects of interferon beta therapy and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Interferon-beta: mechanism of action and dosing issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

The mechanism of action of interferon-β in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Three-dimensional structure of recombinant human interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Interferon-γ: an overview of signals, mechanisms and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Regulation of interferon-gamma during innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

The colony-stimulating factors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

The GM-CSF receptor family: mechanism of activation and implications for disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Purification and characterization of a newly identified growth factor specific for epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Palifermin for oral mucositis after intensive therapy for hematologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Palifermin-associated papular eruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

The cardiovascular effects of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Epoetin-associated pure red cell aplasia: past, present, and future considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Bone morphogenetic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Mechanisms of leptin action and leptin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Leptin: a review of its peripheral actions and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Side effects of alpha interferon in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Side effects of interferon-alpha in treating hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Human interferon alpha-2b: a therapeutic protein for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

PEGylation, successful approach to drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

[Interferon-induced autoimmune thyroiditis in a patient with hepatitis C virus infection].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Pegylated interferon alpha-2B induced lupus in a patient with chronic hepatitis B virus infection: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Lupus activation with cerebritis following pegylated interferon in a hemodialysis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

A case of reversible dilated cardiomyopathy after alpha-interferon therapy in a patient with renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Extremely acute exacerbation of interstitial pneumonia after interferon-alpha treatment for metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Interstitial pneumonitis in a patient with chronic hepatitis C and chronic renal failure on interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Circulating KL-6 level at baseline is a predictive indicator for the occurrence of interstitial pneumonia during interferon treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Multiple sclerosis-like disease secondary to alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Restless legs syndrome due to interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Bell's palsy: a rare complication of interferon therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Bell's palsy associated with IFN-alpha and ribavirin therapy for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Visual loss during interferon-alpha therapy in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Thyroid autoimmunity and dysfunction associated with type I interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Interferon-alpha and autoimmune thyroid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: differential diagnosis and possible pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Pernicious anemia associated with interferon-alpha therapy and chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Rescue of interferon induced bone marrow aplasia in a patient with chronic myeloid leukemia by allogeneic bone marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Pure red cell aplasia caused by pegylated interferon-α-2a plus ribavirin in the treatment of chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Interferons in dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Cutaneous reactions to recombinant cytokine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Systemic lupus erythematosus induced by interferon β1 therapy in a patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Multiple sclerosis, interferon beta and clinical thyroid dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

A rare, treatable cause of relapsing encephalopathy in an MS patient on interferon beta therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Gamma-interferon is one of several direct B cell-maturing lymphokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Recombinant interferon-gamma in the treatment of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Acute respiratory failure after interferon-gamma therapy in IPF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Hemophagocytosis exacerbated by G-CSF/GM-CSF treatment in a patient with myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Profound thrombocytopenia related to G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Sweet's syndrome in chronic lymphocytic leukemia associated with neutropenic fever and granulocyte colony stimulation factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Exacerbation of palmoplantar pustulosis by granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Role of platelet-derived growth factor in wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Platelet-derived growth factor BB for the treatment of chronic pressure ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Fulminant myocarditis owing to high-dose interleukin-2 therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Gastrointestinal perforations associated with interleukin-2 administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Raves and risks for erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

New avenues of exploration for erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Pure red-cell aplasia and epoetin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Bone morphogenetic proteins: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Off-label use of bone morphogenetic proteins in the United States using administrative data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Complications related to osteobiologics use in spine surgery: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Narrative review: the role of leptin in human physiology: emerging clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Desquamative Interstitial Pneumonitis (DIP) occurring during treatment with pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0226-Z

Side effects of therapy of hepatitis C and their management

21 January 2018

1 reference

12 December 2020

[Aortitis after G-CSF injections]

1 reference

12 December 2020

SnapShot: Cytokines I

1 reference

12 December 2020

Adverse effects of interleukin 2

1 reference

12 December 2020

Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra)

1 reference

12 December 2020

Disseminated vascular papules in an immunodeficient patient being treated with granulocyte colony-stimulating factor

1 reference

12 December 2020

A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2

1 reference

12 December 2020

A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer

1 reference

12 December 2020

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

12 December 2020

Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

12 December 2020

Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins

1 reference

12 December 2020

Two different subunits associate to create isoform-specific platelet-derived growth factor receptors

1 reference

12 December 2020

Erythropoietin and hypertension

1 reference

12 December 2020

“Myorhythmia” slow facial tremor from chronic interferon alpha-2a usage

1 reference

12 December 2020

Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2

1 reference

12 December 2020

Coronary vasospasm after interferon administration.

1 reference

12 December 2020

Toxic epidermal necrolysis associated with interleukin-2

1 reference

12 December 2020

Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy

1 reference

12 December 2020

Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma

1 reference

12 December 2020

Anterior ischemic optic neuropathy caused by interferon alpha therapy

1 reference

12 December 2020

1 reference

12 December 2020

Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias

1 reference

12 December 2020

Myocardial injury after interleukin-2 therapy

1 reference

12 December 2020

Acute renal failure during therapy with recombinant human gamma interferon

1 reference

12 December 2020

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

12 December 2020

Two classes of PDGF receptor recognize different isoforms of PDGF

1 reference

12 December 2020

Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group

1 reference

12 December 2020

Interstitial granulomatous drug reaction to anakinra

1 reference

12 December 2020

Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature

1 reference

12 December 2020

Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma

1 reference

12 December 2020

Phase I study of multiple dose intramuscularly administered recombinant gamma interferon

1 reference

12 December 2020

Cutaneous mucinoses complicating interferon beta-1b therapy

1 reference

12 December 2020

Interleukin-11: review of molecular, cell biology, and clinical use.

1 reference

12 December 2020

Anaphylactic reaction to recombinant human erythropoietin

1 reference

12 December 2020

Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms.

1 reference

12 December 2020

Drug-induced systemic lupus erythematosus in interferon beta-1b therapy

1 reference

12 December 2020

Worsening psoriasis after treatment with G-CSF in a patient with small-cell lung cancer

1 reference

12 December 2020

Interleukin-2 associated linear IgA bullous dermatosis

1 reference

12 December 2020

Anaphylactoid reaction to granulocyte colony-stimulating factor used in mobilization of peripheral blood stem cell

1 reference

12 December 2020

Adipocytokines and cancer

1 reference

12 December 2020

Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma

1 reference

12 December 2020

Neurotransmitter changes by interferon-alpha and therapeutic implications

1 reference

12 December 2020

Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis

1 reference

12 December 2020

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

1 reference

12 December 2020

[Seizures during interferon alpha therapy: three cases in dermatology]

1 reference

12 December 2020

Erythroderma after autologous bone marrow transplantation modified by administration of cyclosporine and interferon gamma for breast cancer

1 reference

12 December 2020

Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group

1 reference

12 December 2020

The colony-stimulating factors and cancer

1 reference

12 December 2020

A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy

1 reference

12 December 2020

Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C

1 reference

12 December 2020

SnapShot: cytokines III

1 reference

12 December 2020

Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis

1 reference

12 December 2020

Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions

1 reference

12 December 2020

Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone

1 reference

12 December 2020

Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB.

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).

1 reference

12 December 2020

Crohn disease worsened by anakinra administration

1 reference

12 December 2020

Unusual extramedullary hematopoiesis in a patient receiving granulocyte colony-stimulating factor

1 reference

12 December 2020

Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells

1 reference

12 December 2020

BMP-7 (OP-1) safety in anterior cervical fusion surgery

1 reference

12 December 2020

Molecular mechanisms of erythropoietin signaling

1 reference

12 December 2020

Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection

1 reference

12 December 2020

[Wells' cellulitis and bacterial necrotizing cellulitis induced by anakinra]

1 reference

12 December 2020

Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures

1 reference

12 December 2020

Managing toxicities of high-dose interleukin-2.

1 reference

12 December 2020

Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia

1 reference

12 December 2020

SnapShot: cytokines II

1 reference

12 December 2020

Bell's palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy.

1 reference

12 December 2020

Flare of psoriasis and psoriatic arthritis following treatment with granulocyte colony-stimulating factor

1 reference

12 December 2020

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

12 December 2020

Interferon-induced reversible acute renal failure with nephrotic syndrome

1 reference

12 December 2020

Pericarditis due to interferon-alpha therapy during treatment for chronic hepatitis C.

1 reference

12 December 2020

Septicemia with Staphylococcus aureus, beta-hemolytic streptococci group B and G, and Escherichia coli in a patient with rheumatoid arthritis treated with a recombinant human interleukin 1 receptor antagonist (Anakinra)

1 reference

12 December 2020

Tolerability and side-effect profile of rhIL-11.

1 reference

12 December 2020

The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies

1 reference

12 December 2020

SnapShot: Cytokines IV

1 reference

12 December 2020

Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C.

1 reference

12 December 2020

Granulocyte colony-stimulating factor-induced Sweet syndrome in a healthy donor

1 reference

12 December 2020

Myocardial toxic effects during recombinant interleukin-2 therapy

1 reference

12 December 2020

Erythema exsudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor

1 reference

12 December 2020

10.1007/S40264-014-0226-Z

Identifiers

DOI

1 reference

PubMed ID

25270293

Dimensions Publication ID

1 September 2017

0 references

0 references

1 reference

PubMed ID

25270293